Deucravacitinib (Sotyktu) Meets Main Goals in Phase 3b/4 Scalp PsO Study
More than three times as many patients with scalp psoriasis taking deucravacitinib (Sotyktu, BMS) were clear or almost clear by Week 16 when compared to their counterparts in the placebo arm, according to data from the Phase 3b/4 PSORIATYK SCALP trial. Specifically, 48.5% people taking the oral tyrosine kinase 2 (TYK2) inhibitor showed a statistically […]